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BACKGROUND AND PURPOSE
The α3β4 subtype of nicotinic acetylcholine receptors (nAChRs) has been implicated in mediating nicotine reinforcement
processes. AT-1001 has been recently described as a high-affinity and selective α3β4 nAChR antagonist that blocks nicotine
self-administration in rats. The aim of this study was to investigate the mechanism of action underlying the
nicotine-suppressive effects of AT-1001.
EXPERIMENTAL APPROACH
Effects of AT-1001 were determined using in vitro assays and rat models of nicotine addiction, and compared with varenicline.
KEY RESULTS
AT-1001 and its analogue AT-1012 were functionally selective as antagonists for α3β4 over α4β2 nAChRs, but not to the same
extent as the binding selectivity, and had partial agonist activity at α3β4 nAChRs. In contrast, varenicline was a partial agonist
at α4β2, a weak agonist at α3β4 and inhibited α4β2 at a much lower concentration than it inhibited α3β4 nAChRs. AT-1001
and varenicline also had very different in vivo properties. Firstly, AT-1001 did not exhibit reinforcing properties per se while
varenicline was self-administered. Secondly, systemic treatment with AT-1001 did not induce reinstatement of nicotine seeking
but rather attenuated reinstatement induced by varenicline, as well as nicotine. Finally, unlike varenicline, AT-1001 selectively
blocked nicotine self-administration without altering alcohol lever pressing as assessed in an operant co-administration
paradigm.
CONCLUSIONS AND IMPLICATIONS
These findings describe a more complex AT-1001 in vitro profile than previously appreciated and provide further support for
the potential of AT-1001 and congeners as clinically useful compounds for smoking cessation, with a mechanism of action
distinct from currently available medications.
Abbreviations
EXT, extinction; FR, fixed ratio; HBSS, Hank’s balanced salt solution; MP, membrane potential; NAc, nucleus
accumbens; nAChRs, nicotinic acetylcholine receptors; PR, progressive ratio; TO, time out
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Introduction
Nicotine is the main active ingredient contained in tobacco
leaves that is responsible for the addictive properties associ-
ated with smoking. Nicotine binds to nicotinic acetylcholine
receptors (nAChRs) found in the brain and the periphery.
There is considerable reason to believe that several nAChR
subtypes are involved in nicotine addiction. The greatest
amount of evidence relates to the α4β2 nAChR, by far the
most abundant in the brain and found in high concentra-
tions in reward centres such as the nucleus accumbens (NAc)
and ventral tegmental area (Perry et al., 2002; 2007). Knock-
out of the β2 subunit eliminates nicotine self-administration
in mice (Picciotto et al., 1998; Epping-Jordan et al., 1999),
while knocking in a mutant α4 subunit induces higher sen-
sitivity of the α4β2 nAChR to nicotine and renders mice more
susceptible to self-administration (Tapper et al., 2004). Con-
sistent with a role for α4β2 nAChR in mediating nicotine
reward, varenicline, a partial agonist at this receptor, reduces
nicotine self-administration in rats (Rollema et al., 2007;
George et al., 2011).
In addition to the α4β2, recent genetic and knockout
studies have shown the importance of other nAChR subunits
in nicotine dependence including the α6 and the α5 nAChR
subunit (Pons et al., 2008; Fowler et al., 2011). There is now
considerable evidence that the α3β4 nAChR, highly expressed
in themedial habenula and interpeduncular nucleus, but very
sparsely in most other regions (Marks et al., 2002; Perry et al.,
2002), is also involved in drug reward. Studies using the α3β4
nAChR antagonist 18-methoxycoronaridine have demon-
strated that α3β4 inhibition blocks self-administration of a
large number of abused drugs including nicotine, morphine,
cocaine and alcohol (Glick and Maisonneuve, 2000;
Maisonneuve and Glick, 2003). In agreement, we have
recently reported that AT-1001, a novel α3β4 nAChR ligand
with high affinity and selectivity for this receptor, blocked
nicotine self-administration in rats without affecting operant
responding for food (Toll et al., 2012). In contrast, transgenic
mice with targeted overexpression of β4 nAChRs showed
aversion for nicotine (Frahm et al., 2011).
Currently, the most efficacious smoking cessation medi-
cation used clinically is varenicline (Chantix; Jorenby et al.,
2006; Galanti, 2008). This compound has been hypothesized
to reduce smoking by selectively partially activating α4β2
nAChR (Rollema et al., 2007). However, although binding
studies support the selectivity of varenicline for the α4β2
nAChR, in vitro functional studies have indicated that it fully
activates α3β4 and α7 nAChR at virtually the same concen-
tration at which it partially activates α4β2 nAChR (Mihalak
et al., 2006; Rollema et al., 2007; Chatterjee et al., 2011).
These and other studies have led to the suggestion that the
ability of this compound to block nicotine- and alcohol-
mediated behaviours may be due to stimulation of α3β4
nAChR rather than, or in addition to, partial activation of
α4β2 (Steensland et al., 2007; Baldwin et al., 2011; Chatterjee
et al., 2011).
To better understand the mechanism of action underlying
the nicotine-suppressive properties of AT-1001, we further
analysed the in vitro activities of this compound and its ana-
logue AT-1012, and compared these with varenicline.
AT-1001 and varenicline were also compared with regard to
abuse potential, vulnerability to relapse and selectivity of
nicotine-suppressive effects.
Methods
Cell culture
KXα3β4R2 and KXα4β2R2 cells containing rat α3β4 and α4β2
nAChRs, respectively (obtained from Drs Kenneth Kellar and
Yingxian Xiao, Georgetown University, Washington, DC,
USA), were cultured as described by Wu et al. (2014).
Binding assays
Binding assays were conducted using 0.3 nM [3H]-epibatidine
as the radioligand (Toll et al., 2012). IC50 values and Hill
coefficients were determined by using GraphPad Prism
(GraphPad Software, Inc, La Jolla, CA, USA). Ki values were
calculated using the Cheng–Prusoff transformation (Cheng
and Prusoff, 1973).
Calcium (Ca2+) fluorescence and membrane
potential (MP) assays
nAChR functional activity was determined by measuring
nAChR-induced Ca2+ mobilization (for α3β4 nAChR) or MP
change (for α4β2 nAChR) using the Molecular Devices Ca2+
dye or Membrane Potential Assay Kit (Blue Dye; Molecular
Devices, Sunnyvale, CA, USA) using the FlexStation 3® micro-
plate reader (Molecular Devices). Briefly, HEK cells transfected
Tables of Links
TARGETS
α3 nAChR α6 nAChR
α4 nAChR α7 nAChR
α5 nAChR β2 nAChR
β4 nAChR
LIGANDS
[3H]-epibatidine Mecamylamine
Alcohol (ethanol) Morphine
Cocaine Nicotine
Dopamine Varenicline
These Tables list key protein targets and ligands in this article which are hyperlinked to corresponding entries in http://
www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Pawson et al., 2014) and are
permanently archived in the Concise Guide to PHARMACOLOGY 2013/14 (Alexander et al., 2013).
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with α3β4 or α4β2 nAChRs were seeded in a 96-well plate
(4000 cells per well) 1 day before the experiments. For agonist
assays, after brief washing, cells were loaded with 225 μL of
HBSS assay buffer (Hank’s balanced salt solution with 20 mM
of HEPES, pH 7.4) containing the appropriate dye, and incu-
bated at 37°C. After 30 min, 25 μL solutions of test com-
pounds were dispensed into the wells by the FlexStation and
resulting MP change or Ca2+ fluorescence was recorded every
3 s for 120 s by reading at 565 nM fluorescence excited at
530 nM wavelength for MP, and reading at 525 and excited at
485 for Ca2+ flux. For the antagonist assay, cells were loaded
with 200 μL HBSS buffer containing dye and incubated at
37°C. After 15 min, 25 μL of test compounds was added, and
after another 15 min, 25 μL of epibatidine was added by
the FlexStation to a final concentration of 100 nM, and
fluorescence measured as described above. The change in
fluorescence represents the maximum response, minus the
minimum response for each well. GraphPad Prism was
used to determine the EC50 and IC50 values by plotting the
changes in fluorescence versus the logs of the compound
concentrations.
Animals
Fifty-seven male Sprague-Dawley rats (200–225 g) were
obtained from Charles River (Portage, MI, USA). Rats were
housed in a room with a reverse 12 h light/12 h dark cycle
(lights off at 07:30 h). All experiments were conducted during
the dark phase of the cycle. Animals were acclimatized for 7
days with water and chow (Teklad Diets, Madison, WI, USA)
and handled for 3 days before the experiments were con-
ducted. Throughout all operant procedures, rats were food
restricted and received 16–20 g of chow daily with water
freely accessible. All studies involving animals are reported in
accordance with the ARRIVE guidelines for reporting experi-
ments involving animals (Kilkenny et al., 2010; McGrath
et al., 2010).
Animal welfare and ethical statement
All animal experiments were carried out in accordance with
the National Institutes of Health Guide for the Care and Use
of Laboratory Animals. Consistent with these guidelines,
ongoing statistical testing of data collected was used to mini-
mize the number of animals used within the constraints of
necessary statistical power. All methods used were pre-
approved by the Institutional Animal Care and Use Commit-
tee at the Torrey Pines Institute for Molecular Studies (Port
Saint Lucie, FL, USA).
Apparatus
Self-administration and reinstatement experiments were con-
ducted in operant conditioning chambers (see Supporting
Information).
Food training
One week after arrival, all rats were trained for 3 days to
lever-press for 45 mg food pellets (Test Diet 5-TUM, Rich-
mond, IN, USA) under a fixed ratio-1 (FR-1) schedule of rein-
forcement in 30 min sessions.
I.v. catheterization
I.v. catheterization was performed after operant food training
as previously described (de Guglielmo et al., 2013), except
that rats were anaesthetized via inhalation of isoflurane
(Vetamac, Inc., Rossville, IN, USA. To maintain patency for
the duration of the experiment, catheters were flushed daily
with 0.2 mL of heparin (1000 UPS U·mL−1)-containing saline
solution, which also contained enrofloxacin (0.7 mg·mL−1).
Nicotine self-administration
Following recovery from surgery, animals were trained to
self-administer nicotine (30 μg·kg−1 per infusion) in the same
chambers as the food training sessions using an FR-3 [20 s
time out (TO)] schedule during daily 2 h sessions (Gilpin
et al., 2014) conducted over 7 days. TO was concurrent with
illumination of a cue light located above the active lever to
signal delivery of the positive reinforcement. An intermittent
tone (7 kHz, 70 dB) was sounded throughout the session.
Responses to the inactive lever were recorded and served as a
measure of non-specific motor behaviour. After 7 days on this
reinforcement schedule, the task was switched to progressive
ratio (PR) schedule that better measures motivational pro-
perties rather than rate of drug intake. For the PR procedure,
the response requirement for successive injections was
3, 6, 9, 12, 17, 24, 32, 42, 56, 73, 95, 124, 161, 208, 268, etc.,
based on the formula ‘Response ratio (rounded to nearest
integer) = [5e(0.25×inj. number)] − 5’ (Richardson and Roberts, 1996;
Gamaleddin et al., 2012). The PR schedule used a 20 s TO fol-
lowing each drug infusion. The break point was defined as the
highest ratio completed before a 60 min period during which
no injections were earned and lasted a maximum of 3 h.
Assessment of the reinforcing properties of
AT-1001 and varenicline
Following initial nicotine self-administration using FR3TO20
and PR reinforcement schedules, rats (n = 17) were given
access to saline self-administration under the FR3TO20
schedule for 2 h over 4 consecutive days. This protocol is
sufficient to significantly decrease nicotine-reinforced lever
pressing (Paterson et al., 2010). Saline self-administration
under PR was tested on day 5. Following saline substitution,
one group of animals (n = 9) was allowed to lever-press for
increasing doses of AT-1001 where each dose (0.3, 3.0 and
30 μg·kg−1) was made available weekly according to the 4 day
FR3TO20 and 1 day PR design, whereas another group of
animals (n = 8) was allowed to self-administer varenicline
(20 μg·kg−1). In this second group of animals, nicotine
(30 μg·kg−1) self-administration was also re-established.
Effect of AT-1001 on reinstatement of
nicotine seeking
A new cohort of rats was initially trained to self-administer
nicotine under the FR3TO20 schedule in 2 h sessions for 16
days. After the training period, an extinction (EXT) phase was
conducted for 15 consecutive days. During 1 h EXT sessions,
the lever presses were no longer associated with nicotine
delivery while all cues (i.e. cue light, tone) were presented to
allow for their concomitant EXT. On the day after the last
EXT session, drug prime reinstatement of extinguished nico-
tine self-administration was examined. Reinstatement ses-
sions were conducted under conditions identical to that of
EXT. To evaluate the effect of AT-1001 on nicotine or
varenicline priming-induced reinstatement, rats (n = 6 and 7)
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were administered AT-1001 (0.75, 1.5 and 3.0 mg·kg−1)
or its vehicle in a counterbalanced order (Latin square
design) 10 min before a nicotine or varenicline injection
(0.15 mg·kg−1, s.c., for both). Ten minutes following the final
injection (nicotine or varenicline), animals were placed in the
self-administration chambers and tested for 60 min. To deter-
mine whether an AT-1001 prime alone would induce rein-
statement, 10 min before the beginning of the session,
AT-1001 (0.75, 1.5 and 3.0 mg·kg−1) was administered and
animals (n = 6) tested as described above. A 3 day interval
occurred between drug tests, during which the animals were
subjected to EXT sessions. AT-1001, varenicline and nicotine
doses, time of injection and experimental design were as
described in previous studies (Forget et al., 2010; Le et al.,
2010; Le Foll et al., 2012; Toll et al., 2012).
Assessment of motor behaviour
using SmartCage™
Motor behaviour in freely moving rats (n = 8) was assessed
using SmartCage technology (AfaSci, Inc., Redwood City, CA,
USA; Khroyan et al., 2012; Vazquez-DeRose et al., 2013).
SmartCage uses a USB-cable linked, non-invasive rodent
behaviour monitoring system in conjunction with the ani-
mal’s home cage. Data were analysed automatically using
the Windows-based program CageScoreTM (AfaSci, Inc., Burl-
ingame, CA, USA). Home cage activity variables including
activity counts (counts of breaks in x-, y- and z-axes photo
beams), activity time (min) and distance travelled (cm) were
calculated for 60 min following treatment with AT-1001 (1.5
and 3.0 mg·kg−1) or its vehicle. Doses of AT-1001 were s.c.
administered in a counterbalanced order (Latin square
design) every 3 days.
Effect of AT-1001 and varenicline on
co-administration of i.v. nicotine and
p.o. alcohol
One week after arrival, a new group of rats was exposed to an
intermittent (every other day) 10% (v/v) alcohol exposure
procedure. Alcohol exposure was conducted in the rat home
cages as previously described (Cippitelli et al., 2012). The
procedure lasted until animals attained seven alcohol expo-
sures. Then animals were moved to self-administration cham-
bers for food training followed by i.v. catheter implantation.
After recovery from surgery, rats were moved to a food-
restricted regimen for the duration of the experiment.
Animals were then subjected to co-administration of i.v. nico-
tine and p.o. alcohol. Operant conditions used in this experi-
ment were chosen from previous work (Le et al., 2010).
Following each nicotine infusion, a 20 s TO period occurred,
during which responses at the lever that delivered nicotine
(right lever) did not lead to programmed consequences. Nico-
tine reinforcements were accompanied by concurrent illumi-
nation of a cue light to signal delivery of nicotine. Alcohol
reinforcements were accompanied by a flashing house light
(0.5 s on, 0.5 s off) with a TO period of 20 s during which
responses at the lever that delivered alcohol (left lever) did
not lead to programmed consequences. An intermittent tone
(7 kHz, 70 dB) was sounded throughout the 60 min session.
These self-administration sessions were conducted for 10 days
under an FR-1 schedule and 6 days under an FR-3 schedule for
both reinforcers. Following stable responding, AT-1001 (0.0,
0.75, 1.5 and 3.0 mg·kg−1) or varenicline (0.0 and 1.5 mg·kg−1)
was s.c. administered to rats 10 min before sessions using a
within-subject Latin square design (n = 6 and 7 respectively).
Test sessions were 4 days apart and conducted after two con-
secutive self-administration sessions.
Data analysis
To establish that nicotine replacement by saline led to decrea-
sed responding, the last day of nicotine self-administration
was compared with the last day of saline-reinforced lever
pressing by one-way within-subject ANOVA. Reinforcing prop-
erties of AT-1001 were analysed by comparing the last day of
nicotine self-administration to the last self-administration
day of each drug dose by one-way within-subject ANOVA. The
same approach was employed to analyse reinforcing proper-
ties of varenicline and nicotine, also under the FR-3 schedule.
The non-parametric Friedman’s ANOVA & Kendall’s concord-
ance analysis followed by Wilcoxon matched pairs test was
carried out for PR data. To establish that reinstatement was
successfully induced, responding during the last EXT session
and the respective reinstatement session were separately
compared with the vehicle-treated group by one-way within-
subject ANOVA. The effect of systemic AT-1001 on reinstate-
ment experiments and locomotor activity was analysed using
one-way repeated measures ANOVA with treatment (drug dose)
as a within-subject factor. The same approach was used to
examine the effect of AT-1001 and varenicline on nicotine
and alcohol co-administration while patterns of nicotine and
alcohol intake during their co-administration were analysed
by means of two-way within-subject ANOVA with ‘day’ and
‘reinforcer’ used as within factors. The level of significance
was set at P < 0.05. ANOVAs were followed, where appropriate,
by Student–Newman-Keuls post hoc tests.
Drugs
AT-1001 [N-(2-bromophenyl)-9-methyl-9-azabicyclo [3.3.1]
nonan-3-amine] and AT-1012 were synthesized at Astraea
Therapeutics, Mountain View, CA, USA. (−)-Nicotine hydro-
gen tartrate salt and alcohol were purchased from Sigma (St.
Louis, MO, USA). Varenicline tartrate was purchased from
Tocris Bioscience (Bristol, UK). Alcohol was diluted in water
and made available orally. Solutions of nicotine, varenicline
and AT-1001 for i.v. injections were obtained by dissolving
drugs in 0.9% saline and the pH adjusted to 7.0–7.4 with
3 M sodium hydroxide. Nicotine and varenicline self-
administration doses are reported as free base concentrations.
Systemic solutions of nicotine and varenicline were obtained
by dissolving drugs in 0.9% saline and AT-1001 was sus-
pended in a vehicle containing 2% DMSO, 1% HCl and 97%
hydroxypropyl cellulose. All drugs for systemic treatment
were administered in a 1 mL·kg−1 volume injection and given
by s.c. route of administration.
Results
In vitro functional activity
Previous binding studies have demonstrated that AT-1001
and AT-1012 have high affinity and are selective for α3β4
nAChRs, whereas nicotine and varenicline show greater
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binding selectivity for α4β2 nAChRs (Supporting Information
Table S1; Toll et al., 2012; Wu et al., 2014). To examine the in
vitro functional profile of these compounds, experiments
were conducted on intact α3β4 nAChRs transfected into HEK
cells using a Ca2+ dye to measure increases in intracellular
Ca2+. In these experiments, both AT compounds exhibited
partial agonist activity when tested alone. AT-1001 and
AT-1012 had EC50 values of 1.7 and 0.98 μM, respectively,
with approximately 35% stimulation compared with nico-
tine, whereas varenicline induced approximately 25% stimu-
lation at the α3β4 nAChR at 10 μM, the highest
concentration that could be tested due to solubility (Table 1
and Figure 1A). This is different than published data showing
full agonist activity at approximately 1.0 μM in cells trans-
fected with human α3β4 nAChRs (Chatterjee et al., 2011).
AT-1001, AT-1012 and varenicline were also tested for func-
tional activity on HEK cells transfected with α4β2 nAChRs.
Because Ca2+ mobilization cannot be measured when using
the α4β2 nAChR-transfected HEK cells (Fitch et al., 2003),
functional experiments with α4β2 nAChRs were conducted
using the MP assay. AT-1001 and AT-1012 displayed very little
agonist activity at α4β2 nAChRs, compared with epibatidine
and varenicline, stimulating approximately 30% at 10 μM,
the highest concentration that could be tested (Figure 1B).
Consistent with previous evidence (Rollema et al., 2007),
varenicline was a partial agonist with approximately 50%
efficacy at α4β2 nAChR and an EC50 of 570 nM.
HEK cells containing nAChRs were then pretreated with
compounds to determine their ability to block epibatidine-
induced cellular activation. AT compounds and varenicline
blocked epibatidine-induced Ca2+ mobilization in α3β4
nAChR-transfected HEK cells (Figure 1C), as reported previ-
ously (Toll et al., 2012). Inhibitory activity of AT-1001 and
AT-1012 against the α4β2 nAChR occurred at IC50 concentra-
tions a few fold higher than on α3β4 nAChR HEK cells.
Varenicline, however, was very potent when inhibiting α4β2
nAChR (Figure 1D), with an IC50 of 0.6 nM, similar to its
binding affinity at this site (Rollema et al., 2007), indicating
that it inhibits α4β2 nAChRs (probably by desensitization) at
concentrations far lower than it stimulates α4β2, or inhibits
α3β4 nAChRs (Chatterjee et al., 2011).
In summary, AT-1001 and AT-1012 appear to have partial
agonist activity at rat α3β4 nAChRs. These compounds can
also stimulate α4β2 nAChRs but at considerably higher con-
centrations. They can also act as functional antagonists at
both receptors with a threefold higher inhibitory potency at
the α3β4 nAChR. At the α3β4 nAChR, it is possible that the
‘antagonism’ is a function of receptor desensitization as well
as direct antagonism of the agonist response. In contrast,
varenicline was a partial agonist at α4β2 nAChR and a weak
agonist at α3β4 nAChRs, but it inhibits α4β2 at a much lower
concentration than it inhibits α3β4 nAChRs, indicating sig-
nificant selectivity as a functional antagonist.
Assessment of the reinforcing properties of
AT-1001 and comparison with varenicline
and nicotine
Both AT-1001 and varenicline potently block self-
administration of nicotine in rats but varenicline has also
been demonstrated to be self-administered as readily as nico-
tine (Paterson et al., 2010). Accordingly, the reinforcing
effects of AT-1001 were examined to determine whether the
α3β4 or α4β2 nAChR partial agonist activity was sufficient
to sustain nicotine self-administration. Following stable
responding for nicotine using an FR-3 schedule of reinforce-
ment (26.9 ± 2.2 response rate on the last day), saline was
substituted for nicotine. As expected, saline decreased lever
responding compared with nicotine (F(1,8) = 88.7, P < 0.001).
Following saline substitution, various doses of AT-1001
induced low levels of responding that were significantly
lower than nicotine and comparable to saline controls (F(4,32)
= 58.3, P < 0.001, Figure 2A).
The findings obtained using the PR reinforcement sched-
ule, with AT-1001, were similar to those obtained using the
FR-3 schedule of reinforcement (Figure 2B). There was signifi-
cantly less motivation for self-administration of AT-1001 or
saline when compared with nicotine (P < 0.05). The break
point obtained with all doses of AT-1001 was similar to that of
saline.
In a separate group of animals, following stable respond-
ing for nicotine self-administration (25.8 ± 2.7, response
rate on the last day) and decreased responding following
Table 1
Functional activity of nicotinic compounds in HEK cells
Inhibition Stimulation
α3β4 α4β2 α3β4 α4β2
Compound IC50 (nM) IC50 (nM) EC50 (nM) Stimulation (%) EC50 (nM) Stimulation (%)
Epibatidine 30.5 ± 4.8 0.10 ± 0.02 42.5 ± 6.40 85.60 ± 11 10.0 ± 0.6 106.1 ± 15.4
Nicotine ND 4.00 ± 0.47 32 995 ± 1735 100 ± 0 1 285 ± 65 100 ± 0
Acetylcholine ND 37.8 ± 1.05 548 ± 190 125 ± 9.8 1 645 ± 505 111.9 ± 3.6
AT-1001 91 ± 41 276 ± 185 1722 ± 330 38.1 ± 0.90 >10 000 ≈25
AT-1012 62 ± 46 167 ± 51 976 ± 5.21 33.5 ± 1.61 >10 000 ≈25
Varenicline ND 0.61 ± 0.18 >10 000 ≈25 569 ± 123 51.2 ± 1.2
The experimental data are presented as mean ± SEM. The experiments were performed in triplicate and repeated three to four times. ND,
not determined.
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saline substitution (F(1,7) = 77.7, P < 0.001), the reinforcing
effects of varenicline under an FR-3 schedule of reinforce-
ment were assessed (Figure 2C). Varenicline was self-
administered (F(3,21) = 13.7, P < 0.001), where post hoc tests
indicated a significant increase in responding compared with
saline self-administration (P < 0.01). Similar to varenicline,
using this 4 day schedule, re-exposure to nicotine also
increased response rates (P < 0.01).
Using the PR schedule of reinforcement (Figure 2D),
varenicline only showed a trend to increase the break point (P
= 0.06) compared with saline, whereas break point levels
following the second exposure to nicotine returned to those
seen during the first nicotine self-administration session (P <
0.05).
Effect of AT-1001 on reinstatement of
nicotine seeking
Lever pressing activity during nicotine self-administration
training and EXT is shown in Supporting Information Fig. S1.
Treatment with AT-1001 in the absence of stimuli that
triggered reinstatement caused decreased lever pressing on
the nicotine-associated lever as compared with vehicle treat-
ment (F(3,15) = 8.6, P < 0.01). A significant reduction at the dose
of 3.0 mg·kg−1 (P < 0.01) was observed on post hoc analysis
(Figure 3A).
As shown in Figure 3B, ANOVA analysis performed on
the nicotine-associated lever indicated a main effect of
0.15 mg·kg−1 nicotine priming in inducing nicotine-seeking
behaviour, as compared with EXT conditions (F(1,5) = 31.8, P <
0.01). In examining the effect of pretreatment of AT-1001
before the priming injection of nicotine, the overall ANOVA
indicated a significant effect such that AT-1001 dose-
dependently decreased responding to a nicotine prime
(F(3,15) = 14.1, P < 0.001). Post hoc comparisons revealed that
doses of 1.5 and 3.0 mg·kg−1 significantly decreased respond-
ing (P < 0.01 and P < 0.001 respectively).
Because of its α4β2 agonist activity, we examined the
ability of a priming dose of varenicline to induce reinstate-
ment of extinguished nicotine self-administration and
whether AT-1001 could attenuate this effect. A priming dose
of varenicline (0.15 mg·kg−1) induced reinstatement of nico-
tine seeking conducted in a preliminary test after 12 EXT days
(see Supporting Information Fig. S2). Therefore, in a subse-
quent experiment, we examined whether pretreatment of
AT-1001 reduced reinstatement induced by varenicline. Reli-
ably, ANOVA revealed that reinstatement of nicotine seeking
was successfully induced by varenicline (0.15 mg·kg−1) com-
pared with EXT conditions as indicated by changes in lever
pressing (F(1,6) = 16.3, P < 0.01). ANOVA analysis indicated that
pretreatment with AT-1001 attenuated responding induced
by a priming injection of varenicline (F(3,18) = 13.1, P < 0.001).
Post hoc comparison tests revealed that all doses of AT-1001
resulted in a diminished number of responses as compared
with those of varenicline alone (P < 0.01 for 0.75 and
1.5 mg·kg−1, P < 0.001 for 3.0 mg·kg−1 dose, Figure 3C).
Figure 1
Stimulating and inhibitory activity of AT compounds and varenicline on α3β4 and α4β2 nAChRs stably expressed in HEK cells. (A) The stimulating
effect on α3β4 nAChRs as measured by a calcium (Ca2+) fluorescence assay. (B) Stimulating effect on α4β2 nAChRs measured by MP fluorescence
assay. (C) Inhibition of 100 nM epibatidine-induced Ca2+ fluorescence by AT compounds and varenicline in HEK cells containing α3β4 nAChRs.
(D) Inhibition of 100 nM epibatidine-induced MP fluorescence by AT compounds and varenicline in HEK cells containing α4β2 nAChRs. Data
shown are mean ± SEM from a single experiment conducted in triplicate that was repeated at least three times with similar results.
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Locomotor activity following
AT-1001 treatment
AT-1001 did not alter home cage activity at the doses exam-
ined. No significant changes were observed for active counts
(F(2,14) = 2.3, NS), distance travelled (F(2,14) = 1.0, NS) and active
time (F(2,14) = 2.3, NS) measured for 60 min following treat-
ment (Supporting Information Fig. S3).
Effect of AT-1001 on operant
co-administration of i.v. nicotine and
p.o. alcohol
Because varenicline is effective at inhibiting alcohol con-
sumption in addition to nicotine self-administration,
AT-1001 was tested to determine whether it was equally effec-
tive in blocking nicotine and ethanol intake in a model of
co-administration of i.v. nicotine and p.o. 10% ethanol. As
shown in Figure 4A, 10 training sessions under an FR-1 sched-
ule were sufficient for rats to concurrently self-administer
nicotine and alcohol. Overall, ANOVA revealed a main effect of
days (F(9,45) = 7.4, P < 0.001) accompanied by ‘reinforcer’ ×
‘day’ interaction (F(9,45) = 6.3, P < 0.001) to suggest different
patterns of intake for nicotine and alcohol. Post hoc analysis
showed escalation of alcohol consumption, as a significantly
different intake was found between the first and the last 4
days of exposure. However, nicotine-reinforced lever pressing
did not change significantly over time. On FR-3 schedule,
alcohol and nicotine were self-administered in a similar
manner [‘reinforcer’ × ‘day’ interaction (F(5,25) = 0.4, NS)],
which allowed us to conduct drug testing on comparable
levels of lever pressing for nicotine and alcohol. Pretreatment
with AT-1001 caused decreased responding on the nicotine-
associated lever as compared with nicotine alone (0 mg·kg−1
treatment, F(2,10) = 11.9, P < 0.01) with post hoc comparisons
Figure 2
AT-1001 (0.3, 3.0 and 30 μg·kg−1) made available i.v. is not self-administered more than saline under fixed ratio-3 (FR-3) and PR reinforcement
schedules. Conversely, i.v. exposure to varenicline (20 μg·kg−1) and nicotine (30 μg·kg−1) increases self-administration in these tasks. (A) and (C):
black circles represent baseline infusion values (±SEM) in 2 h of the last nicotine self-administration session at the training dose of 30 μg·kg−1. Bars
are the mean values (±SEM) of the last FR-3 self-administration session for the corresponding reinforcers. There was a significant increase in
varenicline- and nicotine- but not in AT-1001-reinforced lever pressing as compared with responses of the same rats (n = 8 and 9, respectively)
that self-administered saline; #P < 0.05, ##P < 0.01, ###P < 0.001 difference from mean of the last training day; **P < 0.01 difference from saline
responses. (B) and (D): bars represent break point values (final ratio completed ±SEM) for the corresponding reinforcers during the PR schedule.
There was no increase in motivation to obtain various doses of AT-1001 while varenicline and re-exposure to nicotine produced a trend to increase
and significant increase, respectively, in break point as compared with responses of the same rats that self-administered saline under the PR
schedule. #P < 0.05, ##P < 0.01 difference from nicotine responses; *P < 0.05 difference from saline responses. For detailed statistics, see ‘Results’.
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showing significance at 1.5 mg·kg−1 of AT-1001 (P < 0.01,
Figure 4B). Conversely, alcohol lever pressing was not altered
following AT-1001 treatment (F(2,10) = 0.7, NS). Varenicline
potently reduced nicotine (F(1,6) = 39.1, P < 0.001) as well as
alcohol (F(1,6) = 14.3, P < 0.01) taking behaviour (Figure 4C).
Discussion and conclusions
The novel compound AT-1001 previously demonstrated to
block nicotine self-administration in rats (Toll et al., 2012)
was tested in comparison with the clinically used compound
varenicline to better understand the mechanism of action of
its nicotine-suppressive effects. We show that the two com-
pounds have very different in vitro and in vivo properties.
Unlike AT-1001, the α4β2 nAChR partial agonist varenicline
is self-administered by rats and is able to reinstate extin-
guished nicotine self-administration. AT-1001 appears to be a
more selective inhibitor of nicotine taking and seeking, as it
reduces nicotine self-administration at doses that do not
affect alcohol lever pressing and attenuates reinstatement
induced by both nicotine and varenicline prime. The in vitro
profiles are also significantly different, although both show
discrepancies between binding and functional selectivity.
The in vitro profile of AT-1001, like that of varenicline and
other nAChR ligands, is complicated. Although the original
manuscript on AT-1001 (Toll et al., 2012) discussed this com-
pound as being a selective antagonist at α3β4 nAChRs, the
present data suggest that it has partial agonist activity in cells
that are made up of rat α and β subunits. Recent reports also
show that AT-1001 has partial agonist activity at the human
α3β4 nAChR (Bowman Dalley et al., 2013; Zaveri et al., 2014).
In addition, although this compound and its analogue
AT-1012 clearly have excellent selectivity in binding experi-
ments, they appear far less selective when it comes to in vitro
functional activity, acting as antagonists at the α4β2 nAChR
at concentrations only threefold higher than antagonist
potency at α3β4 nAChR. This is reminiscent of varenicline,
which has nearly 1000-fold higher binding affinity at α4β2
than α3β4 nAChR, but can act as a partial agonist at α4β2 at
virtually the same concentration at which it is an agonist at
α3β4 nAChR (Chatterjee et al., 2011). Measuring functional
activity in transfected cells has another complicating factor. It
is well known that the activity of ligands for both in vitro and
in vivo actions can depend a great deal on the particular
functional assay, and that potency and relative maximal
Figure 3
(A) Systemic injection of AT-1001 (0.0, 0.75, 1.5 and 3.0 mg·kg−1,
s.c.) does not elicit reinstatement per se. Values represent the mean
(±SEM) number of total responses of (n = 6) rats on the nicotine-
associated lever in 60 min. AT-1001 at 3.0 mg·kg−1 reduced response
levels shown during EXT. Systemic injection of AT-1001 (0.0, 0.75,
1.5 and 3.0 mg·kg−1, s.c.) suppresses (B) nicotine priming- and (C)
varenicline priming-induced reinstatement of nicotine seeking.
Values represent the mean (±SEM) number of total responses on the
nicotine-associated lever in 60 min. There was a significant reinstate-
ment induced by nicotine (0.15 mg·kg−1, s.c.) and varenicline
(0.15 mg·kg−1, s.c.), as indicated by responses in rats (n = 6 and 7,
respectively) exposed to these stimuli (in the absence of reward
delivery) compared with EXT responding; ##P < 0.01 versus last day
of EXT. There was a significant main effect of AT-1001 treatment and
a significant suppression of responding at dosages of 1.5 and
3.0 mg·kg−1 on post hoc analysis. AT-1001 0.75 mg·kg−1 dose signifi-
cantly attenuated varenicline-induced reinstatement. **P < 0.01, ***P
< 0.001 difference from vehicle (0.0 mg·kg−1) treated controls. For
detailed statistics, see ‘Results’.
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activity are a function of receptor number (Kenakin, 1985).
This makes the determination of receptor potency and activ-
ity more variable than receptor binding affinity, and differ-
ences in receptor number in the transfected cells, or perhaps
species differences, could explain why Chatterjee et al. (2011)
found full agonist activity for varenicline in cells transfected
with human α3β4 nAChRs, and we observed significantly
weaker activity in cells transfected with rat α3β4 nAChRs.
The study of agonists and antagonists is also very difficult
in nAChRs due to rapid desensitization. In fact, using assays
such as FlexStation or Rb+ flux measurements, it can be very
difficult to differentiate between antagonist activity and
desensitization. One method would be to follow the
re-sensitization of the receptor. We conducted such experi-
ments in which cells were pretreated with AT-1001 or the
agonist nicotine, and then washed at various times before
epibatidine-induced cellular activation. In these experiments,
epibatidine was fully effective as soon as we could activate
receptors after washing away the agonists (L. Toll, unpubl.
obs.). Unfortunately, these experiments did not distinguish
between receptor inhibition versus desensitization with the
receptor rapidly re-sensitizing after AT-1001 treatment. Ulti-
mately, it is unclear whether there is a functional difference
between desensitization and antagonist activity. In either
case, the receptor is in an inactive state and agonists do not
function. This is probably why both agonists and antagonists
can have similar actions in a variety of behavioural responses
including blockade of nicotine self-administration, as
observed for the partial agonists varenicline and sazetidine-A
and the antagonist mechamylamine (Watkins et al., 1999;
Rollema et al., 2007; Levin et al., 2010). Accordingly, regard-
less of partial agonist activity, AT-1001 is a functional antago-
nist of α3β4 nAChRs.
The studies described here do not conclusively prove the
mechanism of action of either AT-1001 or varenicline.
However, they do demonstrate that the two compounds work
differently when compared directly, despite the fact that they
both block nicotine-taking behaviour at similar doses. This
direct comparison is necessary because there seems to be
some variability in the actions of varenicline. Le Foll et al.
(2012) demonstrated that varenicline blocks cue-induced
reinstatement of nicotine seeking, while O’Connor et al.
(2010) found that varenicline attenuated reinstatement
induced by nicotine prime, and prime plus cue, but not by
cue alone. We found that AT-1001 also very potently blocked
relapse-like behaviour when induced by nicotine priming.
However, rather than blocking nicotine prime-induced rein-
statement, varenicline actually induced reinstatement. This
result is different from published data, which demonstrated
no induction of nicotine seeking by varenicline (O’Connor
et al., 2010). However, in that study, doses higher than
0.15 mg·kg−1 varenicline were examined, which may account
for this discrepancy. As expected, AT-1001 also blocked
varenicline-induced reinstatement of nicotine seeking
without inducing reinstatement on its own. Rather, extinc-
tion responding was decreased by 3.0 mg·kg−1 AT-1001, a dose
that decreased responding compared with the extinction
level in each reinstatement experiment, perhaps suggesting
the occurrence of non-specific effects at this dose. Testing the
home cage activity using SmartCage (Khroyan et al., 2012;
Vazquez-DeRose et al., 2013), we found no significant
changes in the locomotor activity at any dose (Supporting
Information Fig. S3).
The rewarding aspect of varenicline is also demonstrated
in its ability to be self-administered per se, an effect consistent
with evidence showing that partial α4β2 nAChR activation is
sufficient to mimic discriminative stimulus and reinforcing
properties of nicotine (Paterson et al., 2010). However, under
a PR reinforcement schedule, rats worked for varenicline to a
Figure 4
Rats (n = 6) self-administer both nicotine (30 μg·kg−1) and 10% (v/v)
alcohol in the operant co-administration paradigm. AT-1001
potently decreases nicotine-reinforced lever pressing leaving alcohol
self-administration unaltered. (A) Training for co-administration of
nicotine and alcohol under both FR-1 and FR-3 reinforcement sched-
ules in 60 min sessions. Symbols represent the mean (±SEM) number
of nicotine and alcohol rewards. *P < 0.05, **P < 0.01 difference from
nicotine reinforcement; ##P < 0.01, ###P < 0.001 versus mean of the
first co-administration session. (B) and (C) are mean (±SEM) of nico-
tine and alcohol rewards in 60 min obtained following systemic
treatment with AT-1001 (0.0, 0.75 and 1.5 mg·kg−1, n = 6) and
varenicline (0.0 and 1.5 mg·kg−1, n = 7) respectively. P < 0.05, **P <
0.01, P < 0.001 difference from vehicle (0.0 mg·kg−1) treatment. For
detailed statistics, see ‘Results’.
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lesser extent than for nicotine, indicating reduced motivation
to obtain the reward, probably due to its lower efficacy at
α4β2 nAChRs. AT-1001 is very different and is not self-
administered by rats at all, consistent with very low in vitro
efficacy at α4β2 nAChRs.
To further explore whether AT-1001 and varenicline act
through distinct mechanisms, we sought to separate their
effects by looking at selectivity in altering reinforcing prop-
erties of other drugs. Because varenicline can reduce nicotine
as well as alcohol self-administration and reinstatement at
similar doses (Steensland et al., 2007; Chatterjee et al., 2011),
AT-1001 and varenicline were tested in an operant
co-administration paradigm in which i.v. nicotine and p.o.
alcohol were simultaneously available. When rats were per-
forming comparable levels of nicotine and alcohol lever
pressing, AT-1001 reduced responding for nicotine while
pressing for alcohol was unaltered. Varenicline gave a differ-
ent result, inhibiting both alcohol and nicotine responding
at 1.5 mg·kg−1. These results suggest that α3β4 nAChR
antagonism/desensitization attenuates nicotine but not
alcohol intake and that the effects of varenicline on alcohol-
related behaviours were probably not due to a α3β4-mediated
mechanism, as has been hypothesized previously (Steensland
et al., 2007; Chatterjee et al., 2011).
Based upon the in vitro profile, it is possible that AT-1001
blocks nicotine self-administration through inhibition of
α4β2 rather than α3β4 nAChRs. However, we find this
unlikely because the potency of AT-1001 at α4β2 is less than
that of mecamylamine, yet it is more effective in blocking
nicotine self-administration. AT-1001 is also far less potent
than mecamylamine at blocking nicotine-induced dopamine
release from synaptosomes derived from the NAc (Toll
et al., 2012), suggesting that AT-1001 is not acting through
α4β2 nAChRs, the receptor subtype found most prevalent
in the NAc (Gotti et al., 2010). Furthermore, as discussed,
unlike varenicline, AT-1001 did not block alcohol self-
administration at doses at which it blocked nicotine.
In conclusion, because of agonist activity of AT-1001 at
α3β4, and α4β2 inhibition at slightly higher concentrations
in vitro, it may be difficult to definitively assign its ability to
block nicotine self-administration and priming-induced rein-
statement only to α3β4 nAChR antagonism. It is possible that
inhibition of nicotine self-administration is due to partial
agonism or potentially desensitization of α3β4 nAChRs,
although functionally there may be no difference between
antagonism and desensitization. Regardless of the exact
mechanism of action, these studies indicate that it is clearly
very different from varenicline, which is self-administered in
nicotine-experienced rats, has sufficient agonist activity
(probably through α4β2) to reinstate previously extinguished
nicotine self-administration, and decreases alcohol as well as
nicotine-taking behaviour. These studies also suggest very
strongly that varenicline is not acting through α3β4 nAChRs
in its ability to block nicotine self-administration, as has also
been suggested previously (Baldwin et al., 2011). In fact,
varenicline very possibly blocks nicotine self-administration
not because it is a partial agonist at α4β2 nAChRs, but
because it very potently desensitizes α4β2 nAChRs (i.e. acts as
a functional antagonist). Furthermore, varenicline probably
does not block alcohol self-administration via α3β4 nAChRs
because AT-1001 is ineffective in this procedure. Although
selective for binding, the mechanisms of action of varenicline
and AT-1001 may be very complex, and it is still unclear
whether it would be more efficacious and safer for a pharma-
cotherapy to act at a single receptor or both α3β4 and α4β2
nAChRs. Regardless of the mechanism of action of vareni-
cline, its long-term safety has been questioned due to suicidal
ideation in patients (Ahmed et al., 2013), although in another
recent study varenicline was demonstrated to be well toler-
ated (Evins et al., 2014). The findings described here provide
further support for the potential of AT-1001 and congeners as
potentially safer and clinically useful compounds for
smoking cessation, with a mechanism of action distinct from
currently available medications.
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Figure S1 Lever pressing activity during nicotine self-
administration and extinction (EXT) of responding. Left
panel represents baseline levels of nicotine infusions during
the last 120 min training session (±SEM) under an FR-3 sched-
ule. Right panel represents the number of responses (±SEM)
during 15 consecutive 60 min EXT sessions in rats used to
examine the effects of AT- 1001 on responding in the absence
of stimuli that triggered reinstatement (grey lines/bar), on
nicotine (black lines/bar) and varenicline (white lines/bar)
induced reinstatement of nicotine-seeking behaviour.
Figure S2 A s.c. priming injection of varenicline
(0.15 mg·kg−1) induced reinstatement of nicotine seeking in a
preliminary test carried out after 12 consecutive EXT sessions.
*P < 0.05 difference from the last EXT session.
Figure S3 Locomotor activity as measured by SmartCageTM
over a 60 min period following treatment with AT-1001 (0.0,
1.5 and 3.0 mg·kg−1, s.c.). No significant changes were
observed for home cage activity variables, including (A)
active counts, (B) distance travelled and (C) active time.
Table S1 Binding affinity of nicotinic compounds on α3β4
and α4β2 nAChRs
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